Ecnoglutide, a once-weekly GLP-1 receptor agonist, showed up to 13.2% weight loss over 40 weeks in obese or overweight adults without diabetes in a Phase III...
Yazen, supported by investors like Evli Growth Partners and Helsana HealthInvest, plans to triple growth within three years. With new funding, Yazen will expand from Sweden...